Harriss Currie to Succeed Gerry Haines
Simos Kedikoglou, Chief Executive Officer of Impulse Dynamics, said, “Harriss is a veteran CFO who helped Luminex Corporation grow from zero to $500M in annual revenue and transition from a domestic focus only to global operations with sales worldwide. That experience, combined with his public accounting background and operational savvy, makes him an excellent next financial leader to help us achieve our ambitious growth objectives and continue scaling our business.”
Simos added, “As we make this transition, I want to thank Gerry Haines for helping us achieve many successes since he joined several years ago. Gerry has exemplified financial stewardship and has been an indispensable partner to me, for whom I have great respect. Thanks to his leadership, we are in a much stronger financial position today and are well positioned for achieving our goal of entering the public markets. He was instrumental in our efforts to fund the acceleration of our clinical and product development pipelines and the commercialization of the Optimizer® system for heart failure. We are deeply indebted to Gerry for his dedication and outstanding contributions to Impulse Dynamics and wish him all the best!”
With this transition, Currie assumes leadership of the Impulse Dynamics finance function, including accounting, tax, treasury, audit, investor relations, and the company’s legal, supply chain, and information technology functions. He will report to Simos Kedikoglou. Currie, 60, served over twenty-three years in multiple capacities at Luminex, the last eighteen as Chief Financial Officer, Senior Vice President, Finance and Treasury. His tenure culminated in the 2021 sale of the company to Diasorin S.p.A. Prior to joining Luminex, he served as the Chief Financial Officer, Secretary and Treasurer of SpectraCell Laboratories.
Currie earned his BBA from Southwestern University and his MBA in Finance and Marketing from The University of Texas at Austin. Prior to returning to school for his MBA, Mr. Currie was a certified public accountant with Deloitte.
About Impulse Dynamics
Impulse Dynamics is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company is focused on delivering its proprietary CCM therapy, which is delivered by the company’s Optimizer device, the CE-marked, and FDA-approved treatment verified to improve the quality of life for heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.1 To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.
Impulse Dynamics (USA), Inc.
50 Lake Center Executive Park, 401 Route 73 N, ‐ Building 50 Suite 100
Marlton, NJ 08053
Phone: (856) 642‐9933
Global Vice President, Marketing